Objective: Atherosclerotic coronary heart disease (CHD) continues to be the dominant disease in Western society.
Objective: Atherosclerotic coronary heart disease (CHD) continues to be the dominant disease in Western society. A large material substance of evidence directly linking serum cholesterol of the same heights and CHD risk has stimulated population treatment strategies designed to change into cholesterol and CHD risk. Data indicating a relation between subdued cholesterol and non-CHD risk have, however, remind ofed that cholesterol reduction may not always be desirable. The primary goal of this evaluative review of the available evidence was to answer the following question: Is prevention/regression therapy for CHD safe and effective?
Data sources: Three lines of evidence were reviewed: epidemiologic studies; primary and secondary prevention trials with clinical last points; and secondary prevention trials with quantitative coronary angiography as a surrogate completion point for clinical CHD.
application of mind selection: Original studies and meta-analyses were reviewed. The principal selection criteria for the epidemiologic studies were large size and put offed follow-up; for the trials, randomization and viable clinical (CHD circumstances CHD mortality, total mortality) or angiographic fall of the curtain points.
Data extraction: The data were initially extracted at a single reviewer using habitual qualitative guidelines. The data were then evaluated according to all authors acting as a data interpretation team.
Data synthesis: Overall, the epidemiologic data revealed exces risk of fatal and nonfatal CHD consequences was directly related to total cholesterol and low-density lipoprotein (LDL) cholesterol flushs for both men and women and for the couple younger ([less than] 65 years) and older ([greater than or equal to] 65 years) patients, athwart a wide range of serum cholesterol evens The predictive value was higher in younger men than older men and women although part of this quantitative interaction may be to be ascribed to fewer studies, with fewer conclusion points, in the older and female populations. The CHD issues and CHD mortality, but not total mortality, were consistently reduc in trials of cholesterol-lowering therapy. The regression trials predominantly in CHD patients with high cholesterol values (mean 71 mmol/L) demonstrated improvement in angiographic atherosclerosis in each study. The evidence for elevated risk of non-CHD death at exceedingly low levels of cholesterol is uncertain and controversial. The greatest in quantity likely possibilities for this apparent relationship are unknown confounding variables and the play of chance.
Conclusions: Serum cholesterol evens are directly associated with CHD risk, and there is no gate level below which there is no risk. Reduction of high serum cholesterol evens reduces CHD risk. Whether lipid-lowering and adjunctive antiatherosclerotic therapies are effective and safe in the majority of CHD patients who have desirable or borderline cholesterol plains remains undetermined.
Atherosclerosis, the complexus interaction of serum cholesterol with the cellular constituents of the arterial wall, leading to coronary heart disease (CHD) and other occlusive vascular diseases continues to be the leading cause of morbidity and mortality in adults in lay opened countries. A large corpse of evidence has gradually accumulated directly linking serum cholestrol on a levels and CHD risk.[1-7]
Until lately clinicians tended to undervalue the importance of cholesterol as a modifiable risk factor for CHD A principal contribution to the qualitative change which has occurr in physicians' attitudes towards cholesterol and its potential for effective modification has been the realization that flat modest, but prolonged, reductions in total and low-density lipoprotein (LDL) cholesterol in bodily forms with marked elevation of cholesterol of the same heights is associated with a clinically significant reduction in CHD risk.[8-10] The publication of consensus panels of person specially versed opinion[11,12] has also helped mold contemporary patterns of practice.
Concurrently and perhaps as importantly, therapeutic modalities have been unfolded that can lower serum cholesterol up to 50 percent[13] This event size is greatly beyond what has been seen with previously available cholesterol-lowering therapy, which is more oftentimes in the range of 20 to 25 percent[8] This greater than usual power of the new cholesterol-lowering put drugs intos has helped to capture the attention, and shape the practice patterns, of many clinicians.
by conversion an increased risk of non-CHD death at same low levels of cholesterol has also been suggested[14] This has stimulated an ongoing logomachy which, unless resolved, may diminish physicians' inclination to prescribe appropriate cholesterol-lowering therapy for patients at increased risk for CHD It may also contribute to the unfolding of a negative public attitude toward CHD risk and its clinical reduction.
This review objectively evaluated all the available data linking cholesterol and CHD risk. Its primary goal was to answer the following question: Is prevention/regression therapy for CHD safe and effective? Subsidiary goals were to clarify important deficiencies in our existing knowledge base, in order to provide insights for coming research.
...